Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin

S. Alan McNeill, Timothy B. Hargreave, Christine Geffriaud-Ricouard, Jean Philippe Santoni, Claus Roehrborn

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Objectives. A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha 1-blocker, on PVR volume and any other associated outcome. Methods. Nine hundred fifty-three patients, 42 to 89 years old, with a baseline PVR volume between 50 and 350 mL (mean 106 mL) were enrolled in 11 double-blind controlled studies and received either alfuzosin (n = 607) or placebo (n = 346) for 1 to 6 months. The relationships between the baseline PVR volume measured by transabdominal ultrasound and age, symptoms, maximum flow rate (Qmax), estimated bladder capacity, and prostate-specific antigen level were assessed. The changes in the PVR volume with treatment were evaluated in all available patients at three endpoints (1, 3, and 6 months). Results. At baseline, a PVR volume of 100 mL or greater was observed in 60%, 47%, and 39% of patients with a Qmax less than 8, 8 to 11, and greater than 11 mL/s, respectively (P = 0.001). The bladder capacity was also significantly related to the Qmax (P = 0.0001). No relationship was found between PVR volume and age, symptoms, or prostate-specific antigen level. The changes in the PVR volume with treatment were related to the baseline PVR volume. However, at all endpoints and whatever the baseline PVR volume, the decreases in the PVR volume were significantly (P <0.01) greater with alfuzosin than with placebo. Acute urinary retention occurred in 7 patients (2 [0.3%] of 607 patients taking alfuzosin and 5 [1.4%] of 346 patients taking placebo); 6 of these 7 patients had a baseline PVR volume greater than 100 mL. Conclusions. In this population of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, the PVR volume and bladder capacity were related to the baseline Qmax. Alfuzosin significantly reduced the PVR volume compared with placebo, and this effect was more marked in patients with a high PVR volume at baseline. Acute urinary retention occurred mainly in patients with a PVR volume greater than 100 mL and was less frequent in patients taking alfuzosin than in those taking placebo.

Original languageEnglish (US)
Pages (from-to)459-465
Number of pages7
JournalUrology
Volume57
Issue number3
DOIs
StatePublished - 2001

Fingerprint

Lower Urinary Tract Symptoms
Residual Volume
Prostatic Hyperplasia
Urine
Placebos
Urinary Bladder
Urinary Retention
alfuzosin
Prostate-Specific Antigen
Placebo Effect

ASJC Scopus subject areas

  • Urology

Cite this

Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : Pooled analysis of eleven controlled studies with alfuzosin. / McNeill, S. Alan; Hargreave, Timothy B.; Geffriaud-Ricouard, Christine; Santoni, Jean Philippe; Roehrborn, Claus.

In: Urology, Vol. 57, No. 3, 2001, p. 459-465.

Research output: Contribution to journalArticle

McNeill, S. Alan ; Hargreave, Timothy B. ; Geffriaud-Ricouard, Christine ; Santoni, Jean Philippe ; Roehrborn, Claus. / Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia : Pooled analysis of eleven controlled studies with alfuzosin. In: Urology. 2001 ; Vol. 57, No. 3. pp. 459-465.
@article{ad629b5358e14b4582068898cbee0fd6,
title = "Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: Pooled analysis of eleven controlled studies with alfuzosin",
abstract = "Objectives. A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha 1-blocker, on PVR volume and any other associated outcome. Methods. Nine hundred fifty-three patients, 42 to 89 years old, with a baseline PVR volume between 50 and 350 mL (mean 106 mL) were enrolled in 11 double-blind controlled studies and received either alfuzosin (n = 607) or placebo (n = 346) for 1 to 6 months. The relationships between the baseline PVR volume measured by transabdominal ultrasound and age, symptoms, maximum flow rate (Qmax), estimated bladder capacity, and prostate-specific antigen level were assessed. The changes in the PVR volume with treatment were evaluated in all available patients at three endpoints (1, 3, and 6 months). Results. At baseline, a PVR volume of 100 mL or greater was observed in 60{\%}, 47{\%}, and 39{\%} of patients with a Qmax less than 8, 8 to 11, and greater than 11 mL/s, respectively (P = 0.001). The bladder capacity was also significantly related to the Qmax (P = 0.0001). No relationship was found between PVR volume and age, symptoms, or prostate-specific antigen level. The changes in the PVR volume with treatment were related to the baseline PVR volume. However, at all endpoints and whatever the baseline PVR volume, the decreases in the PVR volume were significantly (P <0.01) greater with alfuzosin than with placebo. Acute urinary retention occurred in 7 patients (2 [0.3{\%}] of 607 patients taking alfuzosin and 5 [1.4{\%}] of 346 patients taking placebo); 6 of these 7 patients had a baseline PVR volume greater than 100 mL. Conclusions. In this population of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, the PVR volume and bladder capacity were related to the baseline Qmax. Alfuzosin significantly reduced the PVR volume compared with placebo, and this effect was more marked in patients with a high PVR volume at baseline. Acute urinary retention occurred mainly in patients with a PVR volume greater than 100 mL and was less frequent in patients taking alfuzosin than in those taking placebo.",
author = "McNeill, {S. Alan} and Hargreave, {Timothy B.} and Christine Geffriaud-Ricouard and Santoni, {Jean Philippe} and Claus Roehrborn",
year = "2001",
doi = "10.1016/S0090-4295(00)01021-9",
language = "English (US)",
volume = "57",
pages = "459--465",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Postvoid residual urine in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia

T2 - Pooled analysis of eleven controlled studies with alfuzosin

AU - McNeill, S. Alan

AU - Hargreave, Timothy B.

AU - Geffriaud-Ricouard, Christine

AU - Santoni, Jean Philippe

AU - Roehrborn, Claus

PY - 2001

Y1 - 2001

N2 - Objectives. A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha 1-blocker, on PVR volume and any other associated outcome. Methods. Nine hundred fifty-three patients, 42 to 89 years old, with a baseline PVR volume between 50 and 350 mL (mean 106 mL) were enrolled in 11 double-blind controlled studies and received either alfuzosin (n = 607) or placebo (n = 346) for 1 to 6 months. The relationships between the baseline PVR volume measured by transabdominal ultrasound and age, symptoms, maximum flow rate (Qmax), estimated bladder capacity, and prostate-specific antigen level were assessed. The changes in the PVR volume with treatment were evaluated in all available patients at three endpoints (1, 3, and 6 months). Results. At baseline, a PVR volume of 100 mL or greater was observed in 60%, 47%, and 39% of patients with a Qmax less than 8, 8 to 11, and greater than 11 mL/s, respectively (P = 0.001). The bladder capacity was also significantly related to the Qmax (P = 0.0001). No relationship was found between PVR volume and age, symptoms, or prostate-specific antigen level. The changes in the PVR volume with treatment were related to the baseline PVR volume. However, at all endpoints and whatever the baseline PVR volume, the decreases in the PVR volume were significantly (P <0.01) greater with alfuzosin than with placebo. Acute urinary retention occurred in 7 patients (2 [0.3%] of 607 patients taking alfuzosin and 5 [1.4%] of 346 patients taking placebo); 6 of these 7 patients had a baseline PVR volume greater than 100 mL. Conclusions. In this population of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, the PVR volume and bladder capacity were related to the baseline Qmax. Alfuzosin significantly reduced the PVR volume compared with placebo, and this effect was more marked in patients with a high PVR volume at baseline. Acute urinary retention occurred mainly in patients with a PVR volume greater than 100 mL and was less frequent in patients taking alfuzosin than in those taking placebo.

AB - Objectives. A pooled analysis was conducted in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia to examine the relationship between the postvoid residual urine (PVR) volume and various clinical characteristics and to assess the effect of alfuzosin, a clinically uroselective alpha 1-blocker, on PVR volume and any other associated outcome. Methods. Nine hundred fifty-three patients, 42 to 89 years old, with a baseline PVR volume between 50 and 350 mL (mean 106 mL) were enrolled in 11 double-blind controlled studies and received either alfuzosin (n = 607) or placebo (n = 346) for 1 to 6 months. The relationships between the baseline PVR volume measured by transabdominal ultrasound and age, symptoms, maximum flow rate (Qmax), estimated bladder capacity, and prostate-specific antigen level were assessed. The changes in the PVR volume with treatment were evaluated in all available patients at three endpoints (1, 3, and 6 months). Results. At baseline, a PVR volume of 100 mL or greater was observed in 60%, 47%, and 39% of patients with a Qmax less than 8, 8 to 11, and greater than 11 mL/s, respectively (P = 0.001). The bladder capacity was also significantly related to the Qmax (P = 0.0001). No relationship was found between PVR volume and age, symptoms, or prostate-specific antigen level. The changes in the PVR volume with treatment were related to the baseline PVR volume. However, at all endpoints and whatever the baseline PVR volume, the decreases in the PVR volume were significantly (P <0.01) greater with alfuzosin than with placebo. Acute urinary retention occurred in 7 patients (2 [0.3%] of 607 patients taking alfuzosin and 5 [1.4%] of 346 patients taking placebo); 6 of these 7 patients had a baseline PVR volume greater than 100 mL. Conclusions. In this population of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia, the PVR volume and bladder capacity were related to the baseline Qmax. Alfuzosin significantly reduced the PVR volume compared with placebo, and this effect was more marked in patients with a high PVR volume at baseline. Acute urinary retention occurred mainly in patients with a PVR volume greater than 100 mL and was less frequent in patients taking alfuzosin than in those taking placebo.

UR - http://www.scopus.com/inward/record.url?scp=0035123416&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035123416&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(00)01021-9

DO - 10.1016/S0090-4295(00)01021-9

M3 - Article

C2 - 11248620

AN - SCOPUS:0035123416

VL - 57

SP - 459

EP - 465

JO - Urology

JF - Urology

SN - 0090-4295

IS - 3

ER -